XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Net Revenue $ 16,024,948 $ 13,044,571 $ 47,300,029 $ 30,526,572
Cost of goods sold 1,751,349 2,228,561 6,064,524 3,991,728
Gross profit 14,273,599 10,816,010 41,235,505 26,534,844
Operating expenses        
Selling, general and administrative expenses 13,877,879 12,062,195 40,658,424 31,865,958
Research and development 986,454 1,061,387 3,480,906 2,333,024
Depreciation and amortization 997,674 814,881 2,580,243 1,556,752
Change in fair value of earnout liabilities (681,753) 109,689 (1,494,910) 173,116
Total operating expenses 15,180,254 14,048,152 45,224,663 35,928,850
Operating loss (906,655) (3,232,142) (3,989,158) (9,394,006)
Other expense        
Interest expense and other (188,294) (188,300)
Share of losses from equity method investment (379,633)
Total other expense (188,294) (188,300) (379,633)
Loss before income taxes (1,094,949) (3,232,142) (4,177,458) (9,773,639)
Income tax benefit 1,702,890 5,844,796
Net loss (1,094,949) (1,529,252) (4,177,458) (3,928,843)
Less: Net loss attributable to noncontrolling interest (34,579) (58,792) (111,455) (98,485)
Net loss attributable to Sanara MedTech shareholders $ (1,060,370) $ (1,470,460) $ (4,066,003) $ (3,830,358)
Net loss per share of common stock, basic $ (0.13) $ (0.18) $ (0.49) $ (0.49)
Net loss per share of common stock, diluted $ (0.13) $ (0.18) $ (0.49) $ (0.49)
Weighted average number of common shares outstanding, basic 8,332,341 8,107,261 8,244,503 7,836,882
Weighted average number of common shares outstanding, diluted 8,332,341 8,107,261 8,244,503 7,836,882